Captopril Tablet
NDC 43547-366
Product Information
Captopril is a ANDA-approved product labeled by Solco Healthcare Us, Llc. Captopril is used to treat high blood pressure (hypertension). It is supplied as a white tablet for oral administration. This product entry covers the primary NDC 43547-366 and 2 associated package configurations. This profile includes active and inactive ingredient UNII references and FDA labeling data.
Primary Identification
Clinical Specifications
Labeler & Regulatory Data
Marketing Timeline
Product Characteristics
ROUND (C48348)
6 MM
8 MM
10 MM
S1
S2
S3
S4
4
Code Structure Chart
Product Details
What is NDC 43547-366?
What are the uses of this product?
What are Active Ingredients of this product?
- CAPTOPRIL 100 mg/1 - A potent and specific inhibitor of PEPTIDYL-DIPEPTIDASE A. It blocks the conversion of ANGIOTENSIN I to ANGIOTENSIN II, a vasoconstrictor and important regulator of arterial blood pressure. Captopril acts to suppress the RENIN-ANGIOTENSIN SYSTEM and inhibits pressure responses to exogenous angiotensin.
Which are the associated UNII Codes?
The UNII codes for the active ingredients in this product are:
- CAPTOPRIL (UNII: 9G64RSX1XD)
- CAPTOPRIL (UNII: 9G64RSX1XD) (Active Moiety)
Which are the Inactive Ingredients associated UNII Codes?
The inactive ingredients are all the component of a medicinal product OTHER than the active ingredient(s). The acronym "UNII" stands for “Unique Ingredient Identifier” and is used to identify each inactive ingredient present in a product. The UNII codes for the inactive ingredients in this product are:
- LACTOSE MONOHYDRATE (UNII: EWQ57Q8I5X)
- MICROCRYSTALLINE CELLULOSE (UNII: OP1R32D61U)
- STARCH, CORN (UNII: O8232NY3SJ)
- STEARIC ACID (UNII: 4ELV7Z65AP)
What is the NDC to RxNorm Crosswalk for this product?
- RxCUI: 308962 - captopril 100 MG Oral Tablet
- RxCUI: 308963 - captopril 12.5 MG Oral Tablet
- RxCUI: 308964 - captopril 50 MG Oral Tablet
- RxCUI: 317173 - captopril 25 MG Oral Tablet
Which are the Pharmacologic Classes of this product?
* Please review the full disclaimer at the bottom of this page.